In a move to bolster its leadership team, Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced the granting of an equity inducement award to Melita Sun Jung, the newly appointed Chief Business Officer.This strategic decision reflects Terns’ commitment to addressing serious diseases through its innovative portfolio of small-molecule product candidates, particularly in the fields of oncology and obesity.The award was made as a significant inducement to attract Ms.Jung to join the company and was a result of the Compensation Committee’s approval in adherence to Nasdaq Listing Rule 5635(c)(4).
Expanding the
Terns Pharmaceuticals is a California-based biopharmaceutical company renowned for its dedication to developing groundbreaking treatments for serious diseases.With a focus on the therapeutic areas of oncology and obesity, the company has successfully built a comprehensive portfolio of small-molecule product candidates.These candidates demonstrate immense potential in addressing unmet medical needs and have garnered significant attention from industry experts and investors alike.
On May 1, 2024, Terns Pharmaceuticals made a crucial addition to its leadership team with the appointment of Melita Sun Jung as the Chief Business Officer.As an experienced executive with a strong track record in business strategy and development within the biopharmaceutical sector, Ms.Jung’s appointment further solidifies Terns’ commitment to drive the growth and success of the company.
To secure the expertise and skills of Ms.Jung, Terns Pharmaceuticals granted her an equity inducement award under the terms of the 2022 Employment Inducement Award Plan, as amended (the Inducement Plan).This award serves as a material incentive for Ms.Jung to accept employment with Terns and contribute her expertise to further advancing the company’s strategic objectives.
The Compensation Committee of Terns Pharmaceuticals’ Board of Directors approved the equity award, ensuring compliance with Nasdaq Listing Rule 5635(c)(4).This rule allows publicly traded companies to grant material inducement awards to new employees, subject to certain conditions.Terns’ decision to utilize this rule reflects the company’s commitment to attracting top talent and rewarding individuals who can make significant contributions to its mission.
By granting this inducement award, Terns Pharmaceuticals not only confirms its recognition of Ms.Jung’s expertise but also emphasizes its dedication to fostering a strong leadership team capable of driving the company’s growth and success.This move aligns with the company’s broader strategy of developing innovative solutions for serious diseases, particularly in the areas of oncology and obesity.
Conclusion:
Terns Pharmaceuticals’ recent announcement of granting an equity inducement award to its new Chief Business Officer, Melita Sun Jung, showcases the company’s commitment to attracting top talent and strengthening its leadership team.As a clinical-stage biopharmaceutical company focused on addressing serious diseases, Terns Pharmaceuticals understands the importance of assembling a team of skilled professionals to drive its mission forward.
The award, approved by the Compensation Committee of the Board of Directors, was a significant inducement to Ms.Jung to join Terns and contribute her expertise to the development of its small-molecule product candidates.By following Nasdaq Listing Rule 5635(c)(4), Terns Pharmaceuticals demonstrates its adherence to governance principles and its commitment to ensuring that exceptional individuals are incentivized to assist in achieving the company’s strategic goals.
Overall, Terns Pharmaceuticals’ inducement award to its new Chief Business Officer highlights the company’s drive to remain at the forefront of biopharmaceutical innovation.With a robust leadership team in place, the company is well-positioned to continue its exemplary work in addressing serious diseases, ultimately bringing positive impact to the medical community and patients worldwide.
Comments